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Meng H. Tan* and Peter ArvanWith this issue, we launch Clinical Diabetes and Endo-
crinology (CDE), a new journal for health researchers
and professionals involved in the care of people with
diabetes and endocrine diseases. CDE is published col-
laboratively by the University of Michigan and our part-
ners at BioMed Central. Our vision is to share new
research and clinical knowledge in diabetes and endo-
crine diseases with the health professional community,
so that ultimately, our patients can have better care.
Each year, new knowledge and treatments for diabetes
and endocrine diseases are uncovered in many parts of
the world. In diabetes, discovery and development of the
11 classes of anti-hyperglycemia medications available
today has spanned over nine decades [Table 1].
These medications have helped to improve glycemic
control, but we need continued advances in understanding
diabetes so that the burden of disease can be decreased
both for individual patients and for society as a whole.
From idea to patient, translational research spans the
spectrum from basic science, to clinical research, to clin-
ical trials, to approval by regulatory agencies. Because as
many as 387 million patients worldwide have been diag-
nosed with diabetes in 2013 [1], we need progress in all
of these areas.
Among other endocrine disorders, genomics will unques-
tionably enhance our understanding and management of
disease. The incidence of thyroid cancer has been increas-
ing steadily [2]. In 2014, it was estimated there were 62,980
new cases of thyroid cancer in the US alone. New know-
ledge in molecular diagnosis [3] of thyroid cancer may
greatly influence the choice of treatments and would bene-
fit those affected. In adrenocortical carcinoma, genomic
studies have allowed us to distinguish two groups of pa-
tients–one with poor prognosis and another with a far
more favorable prognosis [4]. Translational research from
mouse to human studies may lead to new ways to treat
metastatic thyroid cancer [5].* Correspondence: mengt@med.umich.edu
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unless otherwise stated.To have a global impact, new knowledge should be read-
ily available and freely accessible to health professionals
worldwide. Traditionally, this new knowledge has been
shared in print subscription journals, but the internet and
digital publishing has revolutionized this. The seed for
Open Access publications was planted in 1945 [6], but after
a rather long germination period, Open Access publishing
is now growing in leaps and bounds. Between 2000 and
2009 the number of Open Access journals increased from
740 to 4,796 and their combined Open Access articles in-
creased from 19,500 to 191,850 [7]. This has been stimu-
lated by the three calls to action (Budapest Declaration in
2002, Bethesda Statement in 2003, and Berlin Declaration
in 2003) on Open Access publishing, which all advocated
that “peer-reviewed research articles, donated for publica-
tion by authors with no expectation of compensation,
should be available online, free, and with smallest possible
number of usage restrictions” [6]. Indeed, between 2008
and 2014, the number of journals in PubMed Central with
immediate free access has increased from 375 to 1,358 [8].
Consistent with this mandate, CDE is an immediate Open
Access, peer-reviewed, high quality, online scholarly journal
with a focus on clinical diabetes and endocrinology. As the
journal matures, we expect that papers published in CDE
will be indexed in PubMed and other key literature indices,
and when the time comes, we will register with Thomson
Reuters for the journal’s impact factor.
We plan to have a strong international presence and
are already receiving queries from developing as well as
developed nations around the world. With this in mind,
our distinguished international editorial board comprises
of experts from 19 nations and five continents. Our au-
thors and readers will be health professionals who wish
to share new knowledge that may lead to better under-
standing of diabetes and endocrine diseases. With this in
mind, in our first issue, Hahr and Molitch describe clear,
concise and simple guidelines for managing hypergly-
cemia in patients with diabetes complicated by chronic
kidney failure [9]. These will show health professionals
how to safely use anti-hyperglycemia medications toal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Classes of anti-hyperglycemia medications






3. Biguanide-Metformin 1995 (1957 in Europe)
4. Alpha glucosidase inhibitors 1995 (1990 in Germany)
5. Amylin analog 1995
6. Thiazolidinediones 1997
7. Glucagon-like peptide receptor agonists 2005
8. Dipeptidyl-peptidase inhibitors 2006
9. Bile acid sequestrant-Colesevelam 2008
10. Dopamine agonist-Bromocryptine 2009
11. Sodium-glucose co-transporter 2
inhibitors
2013
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In addition, Minanni et al. from Brazil describe their
rare challenging case of fatal factitious Cushing Syn-
drome as an example of Münchhausen’s Syndrome
[10]. It took a team of clinicians and laboratory scien-
tists to solve this case.
Our papers will cover clinical, translational, health care,
epidemiology and healthy policy research. They will include
original research, reviews, selective case reports, clinical
trials, clinical practice guidelines, commentaries, editorials
and others. Together, we aim to promote better care for
people with diabetes and endocrine diseases globally.
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